1. Home
  2. PCRX vs PCN Comparison

PCRX vs PCN Comparison

Compare PCRX & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

N/A

Current Price

$25.41

Market Cap

999.0M

Sector

Health Care

ML Signal

N/A

Logo Pimco Corporate & Income Strategy Fund

PCN

Pimco Corporate & Income Strategy Fund

N/A

Current Price

$11.85

Market Cap

872.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
PCRX
PCN
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
999.0M
872.0M
IPO Year
2010
2001

Fundamental Metrics

Financial Performance
Metric
PCRX
PCN
Price
$25.41
$11.85
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$30.25
N/A
AVG Volume (30 Days)
642.3K
323.3K
Earning Date
04-30-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
107.44
N/A
EPS
0.19
N/A
Revenue
$541,533,000.00
N/A
Revenue This Year
$6.78
N/A
Revenue Next Year
$8.54
N/A
P/E Ratio
$131.68
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$11.40
52 Week High
$27.66
$13.49

Technical Indicators

Market Signals
Indicator
PCRX
PCN
Relative Strength Index (RSI) 44.73 60.57
Support Level $24.61 $11.47
Resistance Level $26.94 $12.09
Average True Range (ATR) 1.00 0.11
MACD -0.25 0.03
Stochastic Oscillator 18.84 100.00

Price Performance

Historical Comparison
PCRX
PCN

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About PCN Pimco Corporate & Income Strategy Fund

PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.

Share on Social Networks: